Biofil Chemicals & Pharmaceuticals Ltd. (BIOFILCHEM) AI Stock Analysis

• Market Cap: ₹487.89M
• Dividend Yield: N/A
• Average Volume (3M): 6.87K
• Price to Earnings (P/E): 172.4
• Beta (1Y): 1.28
• Revenue Growth: 36.76%
• EPS Growth: 433.63%
• Country: IN
• Employees: 26
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.05
• Shares Outstanding: 16,273,800
• 10 Day Avg. Volume: 7,559
• 30 Day Avg. Volume: 6,869
• PEG Ratio: -5.50
• Price to Book (P/B): 3.72
• Price to Sales (P/S): 2.09
• P/FCF Ratio: -34.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹32.00 ▼(-4.73% Downside)
• Action: Reiterated Date: 02/06/26
• Date: Action: Reiterated 02/06/26

The score is driven primarily by mixed financial performance: balance sheet strength offsets weaker recent revenue trends, while cash flow inconsistency and negative free cash flow growth are key risks. Technicals add moderate support with improving short-term momentum, but the stock remains below its 200-day average. Valuation is neutral with a mid-range P/E and no dividend support.

Positive Factors

Balance-sheet strength

A healthy capital structure and manageable leverage provide durable financial flexibility. This buffer supports funding for working capital, tolerating demand shocks, and accessing credit on better terms, reducing bankruptcy risk and enabling strategic investments over the next 2–6 months.

Sustained operating margins

Consistent positive operating margins indicate structural cost discipline and pricing power in core products. Even with revenue variability, preserved EBIT/EBITDA margins point to a resilient operating model that supports cash generation and reinvestment capacity over the medium term.

Lean operating footprint

A small, lean workforce suggests low fixed-cost intensity and operational agility. This structural advantage can help preserve margins during demand fluctuations, enable quicker product or process shifts, and support scalability without proportionate increases in overhead over coming months.

Negative Factors

Revenue decline

A steep year-over-year revenue drop signals weakening demand or market share loss. Reduced top-line scale pressures margin leverage, constrains reinvestment, and makes earnings recovery harder, posing a sustained risk to profitability and growth over the next several quarters.

Inconsistent cash generation

Persistent negative FCF growth and variable operating cash flow undermine funding autonomy. Over 2–6 months this raises reliance on external financing, limits organic investment, and increases risk that capital projects or working-capital needs strain liquidity and strategic flexibility.

Profitability volatility

Volatile net margins reduce earnings predictability and complicate capital allocation. For stakeholders, inconsistent profitability raises uncertainty about sustainable returns and increases the chance that short-term shocks will have outsized impacts on reserves and investment plans over the medium term.

Biofil Chemicals & Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Biofil Chemicals and Pharmaceuticals Limited engages in the pharmaceutical and chemical businesses primarily in India. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride; and plastic dippers and caps. It also provides job work service for manufacturing of pharmaceuticals. The company was incorporated in 1985 and is based in Indore, India.

How the Company Makes Money

null

Biofil Chemicals & Pharmaceuticals Ltd. Financial Statement Overview

Summary

Financials are mixed: a solid balance sheet (manageable leverage, strong equity base) supports stability, but income performance has weakened with the latest revenue decline and profit volatility. Cash flow is the main drag, with inconsistent operating cash generation and negative free cash flow growth due to high capex.

Income Statement

Biofil Chemicals & Pharmaceuticals Ltd. has shown fluctuating revenue and profitability over recent years. The gross profit margin has generally remained stable, but net profit margin has seen some volatility. Revenue has decreased in the latest year, indicating potential market challenges. However, the company has managed to maintain positive EBIT and EBITDA margins, suggesting operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a moderate debt-to-equity ratio, indicating manageable leverage. The equity ratio is strong, reflecting a solid capital structure with a reasonable level of shareholder equity. Return on equity has been positive, though showing some variability, highlighting potential for investor returns.

Cash Flow

Cash flow performance has been mixed, with recent periods showing negative free cash flow growth, driven by high capital expenditures relative to generated cash. The operating cash flow to net income ratio indicates some inconsistency in cash generation from operations, suggesting potential liquidity challenges.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	425.20M	334.02M	400.35M	300.35M	223.82M	357.50M
Gross Profit	19.32M	20.91M	25.28M	25.63M	28.66M	33.23M
EBITDA	36.91M	11.53M	13.06M	12.65M	14.83M	23.99M
Net Income	28.59M	5.58M	7.09M	5.60M	6.98M	12.41M
Balance Sheet
Total Assets	553.64M	509.60M	470.83M	314.06M	187.32M	332.38M
Cash, Cash Equivalents and Short-Term Investments	3.59M	2.55M	22.84M	377.00K	1.45M	4.41M
Total Debt	200.00K	4.71M	4.39M	5.22M	4.65M	4.30M
Total Liabilities	340.59M	321.79M	288.80M	141.04M	18.95M	171.09M
Stockholders Equity	213.04M	187.82M	182.03M	173.01M	168.38M	161.29M
Cash Flow
Free Cash Flow	-36.36M	-20.24M	23.71M	-1.22M	-2.90M	5.44M
Operating Cash Flow	-35.65M	-19.24M	23.94M	-1.12M	-2.20M	11.11M
Investing Cash Flow	41.30M	-1.00M	-229.00K	-106.00K	-699.00K	-961.00K
Financing Cash Flow	-4.61M	-45.00K	-1.25M	151.00K	-58.00K	-8.30M

Biofil Chemicals & Pharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 33.59
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BIOFILCHEM, the sentiment is Negative. The current price of 33.59 is above the 20-day moving average (MA) of 31.23, above the 50-day MA of 32.96, and below the 200-day MA of 39.68, indicating a bearish trend. The MACD of -1.01 indicates Negative momentum. The RSI at 41.13 is Neutral, neither overbought nor oversold. The STOCH value of 32.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BIOFILCHEM.

Biofil Chemicals & Pharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOFILCHEM	63 Neutral	₹487.89M	172.45	―	―	36.76%	433.63%
BALPHARMA	58 Neutral	₹1.08B	16.40	―	1.62%	-9.07%	5.36%
VAISHALI	54 Neutral	₹641.01M	21.33	―	―	18.35%	-154.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MANGALAM	50 Neutral	₹471.37M	-1.11	―	―	-24.55%	-310.57%
LASA	44 Neutral	₹355.72M	-4.63	―	―	-20.40%	-59.20%